Harvard Bioscience Newsroom

Benchmark Co. Sticks to Their Buy Rating for Harvard Bioscience (HBIO)

TipRanksJun 23, 2023 00:26

Benchmark Reiterates Speculative Buy on Harvard Bioscience, Maintains $7 Price Target

BenzingaJun 22, 2023 20:24

Keybanc Adjusts Price Target on Harvard Bioscience to $7 From $5, Maintains Overweight Rating

MT NewswiresApr 26, 2023 21:58

Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Harvard Bioscience (HBIO) and Disc Medicine (IRON)

TipRanksApr 26, 2023 20:41

Keybanc Maintains Overweight on Harvard Bioscience, Raises Price Target to $7

BenzingaApr 26, 2023 17:13

KeyBanc Capital Markets Trims Price Target on Harvard Bioscience to $5 From $7, Maintains Overweight Rating

MT NewswiresNov 10, 2022 00:02

KeyBanc Reaffirms Their Buy Rating on Harvard Bioscience (HBIO)

TipRanksNov 9, 2022 20:40

Harvard Bioscience Analyst Ratings

Benzinga Analyst RatingsNov 9, 2022 17:51

Keybanc Maintains Overweight on Harvard Bioscience, Lowers Price Target to $5

Benzinga Real-time NewsNov 9, 2022 17:50